Medtronic Inc (MDT) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Medtronic Inc (MDT)

83.29

+0.09 (0.11%)

as of Jul 20, 2026, 8:00:00 pm Market Open.

182 watching

Investor Insights

Jul 20, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

Medtronic Inc (MDT-N) has garnered a mix of opinions from experts. One expert sees the company benefiting from advancements in AI technologies, suggesting that boomers continuing to operate in the market serves as a tailwind for growth. Another expert expresses a more cautious outlook, highlighting that while MDT is currently experiencing a positive short- to medium-term phase and is positioned to compete strongly against peers like Boston Scientific, it may lack the research and development prowess to sustain its leadership over the long term. Despite being diversified in its product offerings, which is a strength compared to competitors focused solely on specific device categories, there are concerns about MDT's market position. Upcoming product launches and a perceived undervaluation, with the stock's price-to-earnings ratio being attractive, may support the stock for the next 12-18 months; however, the long-term outlook remains uncertain.

Consensus

Mixed

Valuation

Undervalued

Similar

SYK

BUY

Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.

HOLD

It has grown its dividend 28 consecutive years. Not all of its businesses will be firing. It will not get the same lift because it is not 100% exposed to COVID-19. After COVID the whole diagnostic space will be an interesting one. The dividend is probably relatively safe.

PAST TOP PICK

(A Top Pick Oct 02/19, Up 7%) They reported today and miss expectations. It's a big global company. There's global demand for their medical devices; in Asia, for instance, there's rising heart disease. So, Medtronic can fulfill this demand.

BUY

A large cap diversified company. Their recent acquisition to get into the robotic spine is positive. It has everything for tools and devices, including pacemakers. The chart looks great. This would be the one to own in the space.

BUY

Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.

TOP PICK

They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)

BUY

The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.

HOLD

Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.

BUY

Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.

PAST TOP PICK

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

WEAK BUY

He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.

BUY

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

COMMENT

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

HOLD

Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.

TOP PICK

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

Showing 46 to 60 of 125 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Medtronic Inc (MDT)